The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 5 , Pages 1233-1240 , May 2010

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma

  • Mor-Li Hartman, PhD

      Affiliations

    • Novel Therapeutics Laboratory, Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • ,
  • John Matthew Esposito, BA

      Affiliations

    • Novel Therapeutics Laboratory, Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Beow Yong Yeap, ScD

      Affiliations

    • Hematology-Oncology Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass
    • ,
  • David John Sugarbaker, MD

      Affiliations

    • Novel Therapeutics Laboratory, Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationAddress for reprints: David J. Sugarbaker, MD, The Richard E. Wilson Professor of Surgical Oncology, Chief, Division of Thoracic Surgery, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.

Received 16 April 2009 ,Accepted 21 June 2009.

References 

  1. Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH, Healy-Baldini E, DeCamp MM, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996;224:288–296
  2. Corson JM, Renshaw AA. Pathology of mesothelioma. In:  Aisner J,  Arriagada R,  Green M,  Martini N,  Perry M editor. Comprehensive textbook of thoracic oncology. Baltimore (MD): Williams and Wilkins; 1996;p. 757–758
  3. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120:747–759
  4. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22:7486–7495
  5. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol. 2005;16:345–351
  6. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  7. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889
  8. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993;11:1559–1565
  9. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29–86
  10. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24:6080–6089
  11. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem. 2006;98:723–734
  12. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758
  13. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993;73:585–596
  14. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1995;55:1982–1988
  15. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525–537
  16. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337
  17. Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 2006;66:2305–2313
  18. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008;61:549–558
  19. Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989;74:940–946
  20. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst. 1990;82:582–588
  21. Tanigawa N, Morimoto H, Dohmae N, Shimomatsuya T, Takahashi K, Muraoka R. In vitro growth ability and chemosensitivity of gastric and colorectal cancer cells assessed with the human tumour clonogenic assay and the thymidine incorporation assay. Eur J Cancer. 1992;28:31–34
  22. Sawyers CL. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell. 2003;4:343–348
  23. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–1508
  24. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001;15:2852–2864
  25. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC. mTOR contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem. 2008;283:13021–13030

 Disclosures: None.

 Supported by the International Mesothelioma Program, Brigham and Women's Hospital, Boston, Mass.

PII: S0022-5223(09)00937-4

doi: 10.1016/j.jtcvs.2009.06.027

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 5 , Pages 1233-1240 , May 2010

Article Tools

* Image Usage & Resolution